Findings of the SOCRATES-REDUCED trial (pha.se 2b) revealed that administration of vericiguat in high-risk patients (with worsening HF after clinical stabilization) was safe and resulted in a dose-dependent reduction of NT-proBNP concentration in a short 12-week follow-up [31]. This evidence concerns the gene NPPB and hydrops fetalis.